Skip to main content

10.06.2024 | SHORT COMMUNICATION

Dual Maternal Alloimmunization by Antibodies of Rhesus and MNSs Blood Group System: Case Series and Approach to Work Up in a Resource Limited Set Up

verfasst von: Sangeeta Pahuja, Shruti Chauhan, Geetika Sharma, Deeksha Singh

Erschienen in: Indian Journal of Hematology and Blood Transfusion

Einloggen, um Zugang zu erhalten

Abstract

Backgrounds and Objectives

Maternal alloimmunisation by non D Rh and non Rh antibodies leading to HDFN, is a well established problem encountered in Transfusion medicine and poses a serious threat to our health care system. Presence of multiple alloantibodies, especially if one is masking the other, leads to diagnostic dilemma and delay in transfusion therapy of patients. It is significant to correctly identify highly immunogenic alloantibody specificities in such patients with dual and multiple alloimmunization, by use of various immunohematological techniques.

Case Series

Here, we report three rare and interesting cases. In the first case, anti E was masked by anti s, and lead to HDFN in a neonate due to maternal alloimmunisation. The second case was that of anti S causing severe HDN along with probable presence of anti E. In third case, anti D was masked by anti M, leading to maternal alloimmunization. In the first two cases, both neonates were treated by intravenous immunoglobulins and the latter received DVET. While in the third case, alloimmunization was timely detected during the pregnancy and monitoring of maternal antibody titres was done, ensuring delivery of a healthy baby. After extensive search of literature, we found only one report describing coexistence of anti E and s in a newborn, with baby’s eluate showing only anti s. However, despite being IgG type, it did not cause hemolysis. Literature search revealed that Anti S is a rare cause of HDFN and usually presents as mild jaundice. We did not come across any combination of anti S with anti E, after searching the literature. After extensive search of literature, we came across a single case of dual alloimmunization by anti M obscuring anti D.

Interpretations and Conclusion

The above cases highlight the importance of universal antenatal antibody screening despite Rh D status. It is important to look for clinically significant alloantibodies other than anti-D and correctly identify the culprit antibody, especially, when it is masked by the other multiple alloantibodies. Non D Rh minor blood group incompatibilities e.g. anti-E and anti S or anti s hemolytic disease, should always be considered in the differential diagnosis. A stepwise approach for antibody identification and advanced immunohematological techniques including the use of select cells and adsorption elution methods, can help in elucidating the specificities of antibodies.
Literatur
1.
Zurück zum Zitat Makroo RN, Bhatia A, Gupta R, Phillip J (2013) Prevalence of Rh, Duffy, Kell, Kidd & MNSs blood group antigens in the Indian blood donor population. Indian J Med Res 137(3):521–526PubMedPubMedCentral Makroo RN, Bhatia A, Gupta R, Phillip J (2013) Prevalence of Rh, Duffy, Kell, Kidd & MNSs blood group antigens in the Indian blood donor population. Indian J Med Res 137(3):521–526PubMedPubMedCentral
3.
Zurück zum Zitat Özkaya H, Bahar A, Özkan A, Karademir F, Göçmen İ, Mete Z (2000) İndirekt hiperbilirubinemili yenidoğanlarda ABO, Rh ve subgrup (Kell, c, e) uyuşmazlıkları. Turk Pediatri Ars 35:30–35 Özkaya H, Bahar A, Özkan A, Karademir F, Göçmen İ, Mete Z (2000) İndirekt hiperbilirubinemili yenidoğanlarda ABO, Rh ve subgrup (Kell, c, e) uyuşmazlıkları. Turk Pediatri Ars 35:30–35
4.
Zurück zum Zitat Varghese J, Chacko MP, Rajaiah M, Daniel D (2013) Red cell alloimmunization among antenatal women attending a tertiary care hospital in south India. Indian J Med Res 138(1):68–71PubMedPubMedCentral Varghese J, Chacko MP, Rajaiah M, Daniel D (2013) Red cell alloimmunization among antenatal women attending a tertiary care hospital in south India. Indian J Med Res 138(1):68–71PubMedPubMedCentral
5.
Zurück zum Zitat Naik A, Bhattacharya P, Das P, Mukherjee K, Mukhopadhyay P (2020) Distribution of antenatal alloimmunization in the southern districts of West Bengal and its significant associated factor. Asian J Transfus Sci 14(2):119–125CrossRefPubMedPubMedCentral Naik A, Bhattacharya P, Das P, Mukherjee K, Mukhopadhyay P (2020) Distribution of antenatal alloimmunization in the southern districts of West Bengal and its significant associated factor. Asian J Transfus Sci 14(2):119–125CrossRefPubMedPubMedCentral
6.
Zurück zum Zitat Sidhu M, Bala R, Akhtar N, Sawhney V (2016) Prevalence, specificity and titration of red cell alloantibodies in multiparous antenatal females at a tertiary care centre from North India. Indian J Hematol Blood Transfus 32(3):307–311CrossRefPubMed Sidhu M, Bala R, Akhtar N, Sawhney V (2016) Prevalence, specificity and titration of red cell alloantibodies in multiparous antenatal females at a tertiary care centre from North India. Indian J Hematol Blood Transfus 32(3):307–311CrossRefPubMed
7.
Zurück zum Zitat Jeong BK, Hong KS, Kim OK (1987) A case of hemolytic disease of newborn caused by anti-E. Korean J Clin Pathol 7(2):351–355 Jeong BK, Hong KS, Kim OK (1987) A case of hemolytic disease of newborn caused by anti-E. Korean J Clin Pathol 7(2):351–355
8.
Zurück zum Zitat Geifman-Holtzman O, Wojtowycz M, Kosmas E, Artal R (1997) Female alloimmunization with antibodies known to cause hemolytic disease. Obstet Gynecol 89(2):272–275CrossRefPubMed Geifman-Holtzman O, Wojtowycz M, Kosmas E, Artal R (1997) Female alloimmunization with antibodies known to cause hemolytic disease. Obstet Gynecol 89(2):272–275CrossRefPubMed
9.
Zurück zum Zitat Pal M, Williams B (2015) Prevalence of maternal red cell alloimmunisation: a population study from Queensland, Australia. Pathology 47(2):151–155CrossRefPubMed Pal M, Williams B (2015) Prevalence of maternal red cell alloimmunisation: a population study from Queensland, Australia. Pathology 47(2):151–155CrossRefPubMed
10.
Zurück zum Zitat Joy SD, Rossi KQ, Krugh D, O’Shaughnessy RW (2005) Management of pregnancies complicated by anti-E alloimmunization. Obstet Gynecol 105(1):24–28CrossRefPubMed Joy SD, Rossi KQ, Krugh D, O’Shaughnessy RW (2005) Management of pregnancies complicated by anti-E alloimmunization. Obstet Gynecol 105(1):24–28CrossRefPubMed
11.
Zurück zum Zitat Issitt PD, Anstee DJ (1998) Applied blood group serology, 4th edn. Montgomery Scientific Publications, Durham Issitt PD, Anstee DJ (1998) Applied blood group serology, 4th edn. Montgomery Scientific Publications, Durham
12.
Zurück zum Zitat Mayne KM, Bowell PJ, Green SJ, Entwistle CC (1990) The significance of anti-S sensitization in pregnancy. Clin Lab Haematol 12:105–107CrossRefPubMed Mayne KM, Bowell PJ, Green SJ, Entwistle CC (1990) The significance of anti-S sensitization in pregnancy. Clin Lab Haematol 12:105–107CrossRefPubMed
13.
Zurück zum Zitat Natukunda B, Mugyenyi G, Brand A, Schonewille H (2011) Maternal red blood cell alloimmunisation in southwestern Uganda. Transfus Med 21(4):262–266CrossRefPubMed Natukunda B, Mugyenyi G, Brand A, Schonewille H (2011) Maternal red blood cell alloimmunisation in southwestern Uganda. Transfus Med 21(4):262–266CrossRefPubMed
14.
Zurück zum Zitat Levine P, Kuhmichel AB, Wigod M, Koch E (1951) A new blood factor, s, allelic to S. Proc Soc Exp Biol (N Y) 78:218CrossRef Levine P, Kuhmichel AB, Wigod M, Koch E (1951) A new blood factor, s, allelic to S. Proc Soc Exp Biol (N Y) 78:218CrossRef
16.
Zurück zum Zitat Cohn ClS, Delaney M, Johnson ST, Katz LM (2020) AABB technical manual, 20th edn. American Association of Blood Banks, New York Cohn ClS, Delaney M, Johnson ST, Katz LM (2020) AABB technical manual, 20th edn. American Association of Blood Banks, New York
17.
Zurück zum Zitat Suresh B, Sreedhar Babu KV, Arun R, Jothibai DS, Bharathi T (2015) Prevalence of “unexpected antibodies” in the antenatal women attending the Government Maternity Hospital, Tirupati. J Clin Sci Res 4(1):22–30CrossRef Suresh B, Sreedhar Babu KV, Arun R, Jothibai DS, Bharathi T (2015) Prevalence of “unexpected antibodies” in the antenatal women attending the Government Maternity Hospital, Tirupati. J Clin Sci Res 4(1):22–30CrossRef
20.
Zurück zum Zitat Shahverdi E, Moghaddam M, Gorzin F (2017) Maternal red blood cell alloantibodies identified in blood samples obtained from Iranian pregnant women: the first population study in Iran. Transfusion 57(1):97–101CrossRefPubMed Shahverdi E, Moghaddam M, Gorzin F (2017) Maternal red blood cell alloantibodies identified in blood samples obtained from Iranian pregnant women: the first population study in Iran. Transfusion 57(1):97–101CrossRefPubMed
Metadaten
Titel
Dual Maternal Alloimmunization by Antibodies of Rhesus and MNSs Blood Group System: Case Series and Approach to Work Up in a Resource Limited Set Up
verfasst von
Sangeeta Pahuja
Shruti Chauhan
Geetika Sharma
Deeksha Singh
Publikationsdatum
10.06.2024
Verlag
Springer India
Erschienen in
Indian Journal of Hematology and Blood Transfusion
Print ISSN: 0971-4502
Elektronische ISSN: 0974-0449
DOI
https://doi.org/10.1007/s12288-024-01801-2

Neu im Fachgebiet Onkologie

KI-gestütztes Mammografiescreening überzeugt im Praxistest

Mit dem Einsatz künstlicher Intelligenz lässt sich die Detektionsrate im Mammografiescreening offenbar deutlich steigern. Mehr unnötige Zusatzuntersuchungen sind laut der Studie aus Deutschland nicht zu befürchten.

Welche Krebserkrankungen bei Zöliakie häufiger auftreten

Eine große Kohortenstudie hat den Zusammenhang zwischen Zöliakie und gastrointestinalen Krebserkrankungen und inflammatorischen Krankheiten untersucht. Neben gastrointestinalen Tumoren ist auch ein nicht solider Krebs häufiger.

Adjuvanter PD-L1-Hemmer verhindert Rezidive bei Hochrisiko-Urothelkarzinom

Sind Menschen mit muskelinvasivem Urothelkarzinom für die neoadjuvante platinbasierte Therapie nicht geeignet oder sprechen sie darauf nicht gut an, ist Pembrolizumab eine adjuvante Alternative: Die krankheitsfreie Lebenszeit wird dadurch mehr als verdoppelt.

Duale Checkpointhemmung gegen Melanome verlängert langfristig das Leben

Im Vergleich zu den Überlebenschancen vor der Einführung von Immuncheckpointhemmern (ICI) ist der Fortschritt durch eine ICI-Kombination mit unterschiedlichen Tagets bei fortgeschrittenem Melanom erstaunlich. Das belegen die finalen Ergebnisse der CheckMate-067-Studie und geben Betroffenen "Hoffnung auf Heilung".

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.